Skip to main content
Premium Trial:

Request an Annual Quote

Affy, Basking in AmpliChip Approval, Signs J&J Unit as IVD Customer

NEW YORK, Dec. 28 (GenomeWeb News) - Yesterday's US Food and Drug Administration approval of the AmpliChip is already paying dividends for Affymetrix.

 

Today, the Santa Clara, Calif.-based microarray giant said it has given a Johnson & Johnson company "long-term and comprehensive" access to its GeneChip technology to create and market in vitro diagnostics for certain undisclosed cancers.

The agreement gives Veridex non-exclusive rights to Affy's arrays and instruments. Financial terms of the agreement were not disclosed.

 

As GenomeWeb News reported yesterday, the FDA cleared Roche's long-awaited AmpliChip CYP450 DNA chip and Affy's GeneChip 3000Dx chip reader as an in vitro diagnostic.

 

The approval, announced in an FDA statement on Dec. 23, marks the first time that a DNA chip reader has won FDA clearance for IVD use. The agency also said the clearance may open the door for additional molecular diagnostics based on microarrays to be sold nationwide.

 

The chip and its reader were approved for sale in the European Union in September.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.